AU2399401A - Spiro compounds useful as opioid delta receptor agonist - Google Patents

Spiro compounds useful as opioid delta receptor agonist

Info

Publication number
AU2399401A
AU2399401A AU23994/01A AU2399401A AU2399401A AU 2399401 A AU2399401 A AU 2399401A AU 23994/01 A AU23994/01 A AU 23994/01A AU 2399401 A AU2399401 A AU 2399401A AU 2399401 A AU2399401 A AU 2399401A
Authority
AU
Australia
Prior art keywords
receptor agonist
compounds useful
spiro compounds
delta receptor
opioid delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23994/01A
Other languages
English (en)
Inventor
Masako Imai
Toshiaki Kudo
Tomohisa Mori
Kaori Tadauchi
Masaki Tsushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Publication of AU2399401A publication Critical patent/AU2399401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU23994/01A 1999-12-22 2000-12-21 Spiro compounds useful as opioid delta receptor agonist Abandoned AU2399401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11-364001 1999-12-22
JP36400199A JP2005231995A (ja) 1999-12-22 1999-12-22 オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
PCT/JP2000/009080 WO2001046192A1 (fr) 1999-12-22 2000-12-21 COMPOSES SPIRO UTILES EN TANT QU'AGONISTES DES RECEPTEURS DES OPIOIDES $g(d)

Publications (1)

Publication Number Publication Date
AU2399401A true AU2399401A (en) 2001-07-03

Family

ID=18480738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23994/01A Abandoned AU2399401A (en) 1999-12-22 2000-12-21 Spiro compounds useful as opioid delta receptor agonist

Country Status (3)

Country Link
JP (1) JP2005231995A (ja)
AU (1) AU2399401A (ja)
WO (1) WO2001046192A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438304B1 (en) 2001-10-15 2006-12-06 Janssen Pharmaceutica N.V. Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
PL377047A1 (pl) * 2002-09-09 2006-01-23 Janssen Pharmaceutica, N.V. Hydroksyalkilopodstawione pochodne 1,3,8-triazaspiro [4,5]-dekan-4-onu przydatne w leczeniu zaburzeń, w których pośredniczy receptor ORL-1
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
WO2008001859A1 (fr) * 2006-06-30 2008-01-03 School Juridical Person Kitasato Gakuen AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES
JP2010503669A (ja) 2006-09-12 2010-02-04 アドラー コーポレーション 認知機能の強化のためのｎ含有スピロ化合物の使用
CN103202840B (zh) 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
CN101679430B (zh) 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
JP2016018205A (ja) * 2014-07-11 2016-02-01 株式会社ＳｏｌａｒＦｌａｍｅ 反射鏡およびヘリオスタット装置ならびに太陽熱集熱装置および太陽光集光発電装置
MA41790B1 (fr) 2015-03-17 2022-02-28 Nippon Chemiphar Co Dérivé de morphinane
CN107922403A (zh) 2015-06-26 2018-04-17 武田药品工业株式会社 作为胆碱能毒蕈碱m1受体的调节剂的2,3‑二氢‑4h‑1,3‑苯并噁嗪‑4‑酮衍生物
JP7002335B2 (ja) * 2015-07-03 2022-01-20 エフ．ホフマン－ラ ロシュ アーゲー Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2018030382A1 (ja) 2016-08-09 2018-02-15 国立大学法人 筑波大学 モルヒナン誘導体
US11633392B2 (en) 2016-09-16 2023-04-25 Nippon Chemiphar Co., Ltd. Use of morphinan derivative for therapeutic treatment of opioid delta receptor agonist-related disease
WO2021100878A1 (ja) 2019-11-22 2021-05-27 学校法人北里研究所 ピラゾロモルヒナン誘導体
WO2022181763A1 (ja) 2021-02-26 2022-09-01 学校法人東京理科大学 ストレス関連障害の治療又は予防用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996363A (en) * 1975-06-13 1976-12-07 E. R. Squibb & Sons, Inc. 2-[(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)alkyl]-1H-benz[de]isoquinolin-1,3(2H)-diones
FR2680172B1 (fr) * 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
AU3809999A (en) * 1998-05-18 1999-12-06 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes

Also Published As

Publication number Publication date
WO2001046192A1 (fr) 2001-06-28
JP2005231995A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
AU2399401A (en) Spiro compounds useful as opioid delta receptor agonist
AU2001242744A1 (en) Diphenylalkylamine derivatives useful as opioid delta receptor ligands
IL148119A0 (en) Novel spiro compounds
AU4274401A (en) Diphenylalkylamine derivatives useful as opioid delta receptor agonists
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
AU4772096A (en) Delta opioid receptor antagonists
AU8356798A (en) Delta opioid receptor agonist for reducing ischemic damage
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001264657A1 (en) Crf receptor antagonists
AU3840000A (en) Tricyclic compounds
AU1948601A (en) Triazospiro compounds having nociceptin receptor affinity
AU3195600A (en) Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist
PL350536A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
AU2001295455A1 (en) Indoline derivatives as 5ht2c antagonists
AU5786300A (en) Muscarinic antagonists
AU2001232319A1 (en) Phenoxyalkylamine derivates useful as opioid delta receptor ligands
AU2001232319A2 (en) Phenoxyalkylamine derivates useful as opioid delta receptor ligands
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU2001247357A1 (en) Novel cyclobutene derivatives useful as antagonists of the motilin receptor
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2001263288A1 (en) Crf receptor antagonists
AU2001249144A1 (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor
AU6642900A (en) Improved materials for mycoculture

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase